Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy
Wall Street Zen downgraded shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a report on Saturday...
MarketBeat·2d ago
More News
New South Capital Management Inc. Purchases 31,694 Shares of Royalty Pharma PLC $RPRX
New South Capital Management Inc. lifted its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 1.1% in the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·3d ago
Cookson Peirce & Co. Inc. Buys 338,623 Shares of Royalty Pharma PLC $RPRX
Cookson Peirce & Co. Inc. raised its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 988.3% during the 3rd quarter, according to the company in its most recent filing with the...
MarketBeat·3d ago
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year High - Here's What Happened
Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month High - Should You Buy...
Royalty Pharma (NASDAQ:RPRX - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.38 earnings per share for the quarter, missing the...
MarketBeat·4d ago
Royalty Pharma Q4 Earnings Call Highlights
Royalty Pharma (NASDAQ:RPRX) executives highlighted what they described as a landmark year in 2025, pointing to double-digit top-line growth, continued capital deployment into new royalty deals, and...
MarketBeat·5d ago
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·5d ago
Royalty Pharma Plc Bottom Line Advances In Q4
(RTTNews) - Royalty Pharma plc (RPRX) announced earnings for its fourth quarter that Increased from the same period last year...
Nasdaq News: Markets·5d ago
Royalty Pharma Q4 Earnings Report: What Investors Need to Know
read more...
Benzinga·5d ago
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.